A Multi-Center, Open-label, Pharmacokinetic Drug Interaction Study of AMG 334 and a Combined Oral Contraceptive in Healthy Female Subjects

Trial Profile

A Multi-Center, Open-label, Pharmacokinetic Drug Interaction Study of AMG 334 and a Combined Oral Contraceptive in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Erenumab (Primary) ; Estradiol congener-compounds/progesterone congener compounds
  • Indications Headache; Migraine
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 11 Jun 2017 Results (n=22) presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 08 Jun 2017 According to an Amgen media release, the company will present data from this study at the 59th Annual Scientific Meeting of the American Headache Society 2017.
    • 07 Oct 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top